Analysts expect Baxter International Inc (NYSE:BAX) to post $2.76 billion in sales for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Baxter International’s earnings, with estimates ranging from $2.73 billion to $2.78 billion. Baxter International reported sales of $2.65 billion during the same quarter last year, which would suggest a positive year over year growth rate of 4.2%. The firm is expected to issue its next quarterly earnings report on Wednesday, February 7th.

On average, analysts expect that Baxter International will report full year sales of $2.76 billion for the current financial year, with estimates ranging from $10.52 billion to $10.58 billion. For the next year, analysts forecast that the business will post sales of $11.10 billion per share, with estimates ranging from $10.97 billion to $11.32 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Baxter International.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.05. The company had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.66 billion. Baxter International had a return on equity of 15.00% and a net margin of 9.88%. Baxter International’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.56 EPS.

BAX has been the subject of several analyst reports. Zacks Investment Research downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. Morgan Stanley boosted their price target on Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a report on Thursday, October 26th. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a report on Tuesday, January 2nd. Evercore ISI initiated coverage on Baxter International in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 price target for the company. Finally, Barclays boosted their price target on Baxter International from $70.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $68.64.

In other news, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Third Point Llc sold 5,000,000 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $64.23, for a total value of $321,150,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,061,991 shares of company stock valued at $325,245,035. Insiders own 0.05% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Progressive Investment Management Corp boosted its position in Baxter International by 1.9% during the 4th quarter. Progressive Investment Management Corp now owns 80,097 shares of the medical instruments supplier’s stock worth $5,177,000 after purchasing an additional 1,489 shares during the period. Private Asset Management Inc. purchased a new stake in Baxter International during the 4th quarter worth $205,000. Stillwater Investment Management LLC boosted its position in Baxter International by 271.9% during the 4th quarter. Stillwater Investment Management LLC now owns 75,133 shares of the medical instruments supplier’s stock worth $3,816,000 after purchasing an additional 54,928 shares during the period. Atlantic Trust Group LLC boosted its position in Baxter International by 120.6% during the 3rd quarter. Atlantic Trust Group LLC now owns 58,108 shares of the medical instruments supplier’s stock worth $3,645,000 after purchasing an additional 31,763 shares during the period. Finally, AustralianSuper Pty Ltd purchased a new stake in Baxter International during the 3rd quarter worth $9,871,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

Baxter International (NYSE BAX) opened at $69.28 on Tuesday. The company has a quick ratio of 2.22, a current ratio of 2.80 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $37,750.00, a price-to-earnings ratio of 37.45, a price-to-earnings-growth ratio of 2.08 and a beta of 0.69. Baxter International has a twelve month low of $45.47 and a twelve month high of $69.35.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.92%. Baxter International’s payout ratio is 34.59%.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/09/2-76-billion-in-sales-expected-for-baxter-international-inc-bax-this-quarter.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Get a free copy of the Zacks research report on Baxter International (BAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.